Literature DB >> 17635367

Review article: appropriate use of corticosteroids in Crohn's disease.

P M Irving1, R B Gearry, M P Sparrow, P R Gibson.   

Abstract

BACKGROUND: Corticosteroids are a well-established treatment for active Crohn's disease and have been widely used for decades. It has become apparent, however, that a proportion of patients either fails to respond to corticosteroids or is unable to withdraw from them without relapsing. Furthermore, their use is associated with a range of side effects, such that long-term treatment carries unacceptable risk. AIM: To review the evidence regarding the appropriate use of corticosteroids in Crohn's disease, along with their side effects, safety and alternatives.
METHODS: To collect relevant articles, a PubMed search was performed from 1966 to November 2006 using the terms 'steroid', 'corticosteroid', 'glucocorticoid', 'prednisolone', 'prednisone', 'methylprednisolone', 'hydrocortisone', 'dexamethasone' and 'budesonide' in combination with 'Crohn(s) disease'. Relevant articles were reviewed, as were their reference lists to identify further articles.
RESULTS: When used correctly, corticosteroids are a highly effective, well tolerated, cheap and generally safe treatment for active Crohn' disease. Nevertheless, approximately 50% of recipients will either fail to respond (steroid-resistant) or will be steroid dependent at 1 year. Newer alternatives to corticosteroids are not, however, without risk themselves and, moreover, are not necessarily available universally.
CONCLUSIONS: Steroids are used widely to treat Crohn's disease, a situation that is unlikely to change in the near future. Accordingly, efforts should be made to ensure that they are used correctly and that their side effects are minimized. Reference is made to recently published guidelines and a simplified 'users guide' is presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635367     DOI: 10.1111/j.1365-2036.2007.03379.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

Review 1.  Optimization of conventional therapy in patients with IBD.

Authors:  Kirstin M Taylor; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

2.  Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2018-01-09       Impact factor: 10.864

Review 3.  Optimizing conventional therapies for inflammatory bowel disease.

Authors:  Miles P Sparrow; Peter M Irving; Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 4.  Steroid use and misuse: a key performance indicator in the management of IBD.

Authors:  Jonathan Blackwell; Christian Selinger; Tim Raine; Gareth Parkes; Melissa A Smith; Richard Pollok
Journal:  Frontline Gastroenterol       Date:  2020-04-02

5.  Discovery and preclinical validation of drug indications using compendia of public gene expression data.

Authors:  Marina Sirota; Joel T Dudley; Jeewon Kim; Annie P Chiang; Alex A Morgan; Alejandro Sweet-Cordero; Julien Sage; Atul J Butte
Journal:  Sci Transl Med       Date:  2011-08-17       Impact factor: 17.956

6.  Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease.

Authors:  Joel T Dudley; Marina Sirota; Mohan Shenoy; Reetesh K Pai; Silke Roedder; Annie P Chiang; Alex A Morgan; Minnie M Sarwal; Pankaj Jay Pasricha; Atul J Butte
Journal:  Sci Transl Med       Date:  2011-08-17       Impact factor: 17.956

Review 7.  Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis.

Authors:  Michael F Cunningham; Neil G Docherty; J Calvin Coffey; John P Burke; P Ronan O'Connell
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

8.  Immunomodulation does not alter histology in resected Crohn's disease.

Authors:  F A Frizelle; A Ing; R B Gearry; M Whitehead; I G Faragher; B Dobbs
Journal:  Tech Coloproctol       Date:  2009-09-23       Impact factor: 3.781

Review 9.  Stress and aging act through common mechanisms to elicit neuroinflammatory priming.

Authors:  Laura K Fonken; Matthew G Frank; Andrew D Gaudet; Steven F Maier
Journal:  Brain Behav Immun       Date:  2018-07-17       Impact factor: 7.217

10.  Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease.

Authors:  Duk Hwan Kim; Jae Hee Cheon; Jae Jun Park; Jin Young Yoon; Chang Mo Moon; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2013-01-11       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.